S&P 500   4,637.99 (-0.37%)
DOW   34,890.76 (-0.70%)
QQQ   400.20 (+0.13%)
AAPL   162.23 (+1.24%)
MSFT   335.89 (-0.22%)
FB   335.26 (-0.82%)
GOOGL   2,915.32 (+0.16%)
AMZN   3,575.12 (+0.38%)
TSLA   1,163.84 (+2.36%)
NVDA   332.75 (-0.30%)
BABA   130.27 (-1.02%)
NIO   41.28 (+2.03%)
CGC   11.03 (-0.27%)
AMD   164.29 (+1.47%)
GE   96.46 (-1.97%)
MU   86.32 (+0.21%)
T   23.15 (-3.10%)
F   19.60 (-0.36%)
DIS   146.59 (-0.83%)
ACB   6.51 (+1.09%)
AMC   35.87 (-2.63%)
PFE   53.30 (+1.72%)
BA   196.77 (-0.87%)
S&P 500   4,637.99 (-0.37%)
DOW   34,890.76 (-0.70%)
QQQ   400.20 (+0.13%)
AAPL   162.23 (+1.24%)
MSFT   335.89 (-0.22%)
FB   335.26 (-0.82%)
GOOGL   2,915.32 (+0.16%)
AMZN   3,575.12 (+0.38%)
TSLA   1,163.84 (+2.36%)
NVDA   332.75 (-0.30%)
BABA   130.27 (-1.02%)
NIO   41.28 (+2.03%)
CGC   11.03 (-0.27%)
AMD   164.29 (+1.47%)
GE   96.46 (-1.97%)
MU   86.32 (+0.21%)
T   23.15 (-3.10%)
F   19.60 (-0.36%)
DIS   146.59 (-0.83%)
ACB   6.51 (+1.09%)
AMC   35.87 (-2.63%)
PFE   53.30 (+1.72%)
BA   196.77 (-0.87%)
S&P 500   4,637.99 (-0.37%)
DOW   34,890.76 (-0.70%)
QQQ   400.20 (+0.13%)
AAPL   162.23 (+1.24%)
MSFT   335.89 (-0.22%)
FB   335.26 (-0.82%)
GOOGL   2,915.32 (+0.16%)
AMZN   3,575.12 (+0.38%)
TSLA   1,163.84 (+2.36%)
NVDA   332.75 (-0.30%)
BABA   130.27 (-1.02%)
NIO   41.28 (+2.03%)
CGC   11.03 (-0.27%)
AMD   164.29 (+1.47%)
GE   96.46 (-1.97%)
MU   86.32 (+0.21%)
T   23.15 (-3.10%)
F   19.60 (-0.36%)
DIS   146.59 (-0.83%)
ACB   6.51 (+1.09%)
AMC   35.87 (-2.63%)
PFE   53.30 (+1.72%)
BA   196.77 (-0.87%)
S&P 500   4,637.99 (-0.37%)
DOW   34,890.76 (-0.70%)
QQQ   400.20 (+0.13%)
AAPL   162.23 (+1.24%)
MSFT   335.89 (-0.22%)
FB   335.26 (-0.82%)
GOOGL   2,915.32 (+0.16%)
AMZN   3,575.12 (+0.38%)
TSLA   1,163.84 (+2.36%)
NVDA   332.75 (-0.30%)
BABA   130.27 (-1.02%)
NIO   41.28 (+2.03%)
CGC   11.03 (-0.27%)
AMD   164.29 (+1.47%)
GE   96.46 (-1.97%)
MU   86.32 (+0.21%)
T   23.15 (-3.10%)
F   19.60 (-0.36%)
DIS   146.59 (-0.83%)
ACB   6.51 (+1.09%)
AMC   35.87 (-2.63%)
PFE   53.30 (+1.72%)
BA   196.77 (-0.87%)

Pfizer says COVID-19 pill cut hospital, death risk by 90%

Friday, November 5, 2021 | Matthew Perrone, AP Health Writer


This Feb. 5, 2021, file photo shows the Pfizer logo displayed at the company's headquarters in New York. Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections. The company announced Friday, Nov. 5, it will soon ask the U.S. Food and Drug Administration and international regulators to authorize its pill, which is taken twice a day for five days. (AP Photo/Mark Lennihan, File)

WASHINGTON (AP) — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus.

Currently most COVID-19 treatments require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.

Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.

Since the beginning of the pandemic last year, researchers worldwide have been racing to find a pill to treat COVID-19 that can be taken at home to ease symptoms, speed recovery and keep people out of the hospital.

Having pills to treat early COVID-19 “would be a very important advance," said Dr. John Mellors, chief of infectious diseases at the University of Pittsburgh, who was not involved in the Pfizer study.

“If someone developed symptoms and tested positive we could call in a prescription to the local pharmacy as we do for many, many infectious diseases," he said.

On Friday, Pfizer released preliminary results of its study of 775 adults. Patients who received the company's drug along with another antiviral shortly after showing COVID-19 symptoms had an 89% reduction in their combined rate of hospitalization or death after a month, compared to patients taking a dummy pill. Fewer than 1% of patients taking the drug needed to be hospitalized and no one died. In the comparison group, 7% were hospitalized and there were seven deaths.

"We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer, in an interview.

Study participants were unvaccinated, with mild-to-moderate COVID-19, and were considered high risk for hospitalization due to health problems like obesity, diabetes or heart disease. Treatment began within three to five days of initial symptoms, and lasted for five days. Patients who received the drug earlier showed slightly better results, underscoring the need for speedy testing and treatment.

Pfizer reported few details on side effects but said rates of problems were similar between the groups at about 20%.

An independent group of medical experts monitoring the trial recommended stopping it early, standard procedure when interim results show such a clear benefit. The data have not yet been published for outside review, the normal process for vetting new medical research.

Top U.S. health officials continue to stress that vaccination will remain the best way to protect against infection. But with tens of millions of adults still unvaccinated — and many more globally — effective, easy-to-use treatments will be critical to curbing future waves of infections.

The FDA has set a public meeting later this month to review Merck’s pill, known as molnupiravir. The company reported in September that its drug cut rates of hospitalization and death by 50%. Experts warned against comparing preliminary results because of differences in the studies, including where they were conducted and what types of variants were circulating.

“It’s too early to say who won the hundred meter dash,” Mellors said. “There’s a big difference between 50% and 90% but we need to make sure the populations were comparable.”

Although Merck's pill is further along in the U.S. regulatory process, Pfizer's drug could benefit from a safety profile that is more familiar to regulators with fewer red flags. While pregnant women were excluded from the Merck trial due to a potential risk of birth defects, Pfizer’s drug did not have any similar restrictions. The Merck drug works by interfering with the coronavirus' genetic code, a novel approach to disrupting the virus.

Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.

The drug was first identified during the SARS outbreak originating in Asia during 2003. Last year, company researchers decided to revive the medication and study it for COVID-19, given the similarities between the two coronaviruses.

The U.S. has approved one other antiviral drug for COVID-19, remdesivir, and authorized three antibody therapies that help the immune system fight the virus. But they have to be given by IV or injection at hospitals or clinics, and limited supplies were strained by the last surge of the delta variant.

Shares in New York-based Pfizer Inc. gained 11% to close at $48.61 on Friday.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.7$53.30+1.7%2.93%15.86Hold$49.00
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.